All the news Showing 10 of 17 articles from: GermanyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources NAFLD People with HIV taking newer antiretrovirals at higher risk of fatty liver disease Keith Alcorn / 08 October 2021 People with HIV were more likely to develop fatty liver disease if they took antiretroviral treatment that contains an integrase inhibitor or tenofovir alafenamide (TAF), a German research group has found. Non-alcoholic ... Hepatitis D Bulevirtide appears safe and effective for hepatitis D Liz Highleyman / 28 June 2021 The entry inhibitor bulevirtide (Hepcludex) suppressed hepatitis delta viral load and improved liver enzyme levels in a phase III clinical trial, according to late-breaking study results presented this week at the 2021 International Liver ... Hepatitis delta Combination therapies show promise against hepatitis D Liz Highleyman / 16 December 2019 Combination regimens using lonafarnib or bulevirtide reduced levels of hepatitis delta virus (HDV) in a majority of people with HDV and hepatitis B virus (HBV) co-infection, researchers reported at the AASLD Liver Meeting ... Hepatitis D Bulevirtide is a potential cure for hepatitis B and D Liz Highleyman / 16 April 2019 Bulevirtide, formerly known as Myrcludex B, led to suppression of hepatitis delta virus (HDV) and a functional cure of hepatitis B virus (HBV) in some people with both viruses when combined with pegylated ... Pan-genotypic regimens Pangenotypic hepatitis C drug combinations curing almost all people who complete treatment, real-world studies show Keith Alcorn / 12 April 2019 Once-daily combination pills that can treat all genotypes of hepatitis C infection are curing almost everyone who completes a course of treatment, and drop-out rates during treatment are low, large 'real-world' cohort ... Treatment issues DAAs safe and effective in elderly people with HCV Michael Carter / 05 September 2018 Treatment with direct-acting antivirals (DAAs) is safe and effective in elderly people with hepatitis C virus (HCV) infection, according to German research published in Drugs & Aging. Elderly people (aged 70 years ... Hepatitis D Myrcludex B plus tenofovir suppresses hepatitis delta Liz Highleyman / 30 April 2018 An experimental drug that blocks the entry of hepatitis B virus (HBV) and hepatitis delta virus (HDV) into liver cells suppressed HBV and HDV levels and led to improvement in ... Pan-genotypic regimens 8-week treatment for hepatitis C with Maviret highly effective in people without cirrhosis Keith Alcorn / 13 April 2018 An eight-week course of treatment with the combination of glecaprevir and pibrentasvir (Maviret) is highly effective in curing hepatitis C infection in people without cirrhosis, results of two real-world studies presented at the ... Sex between men High rate of hepatitis C reinfection in German men who have sex with men Keith Alcorn / 03 November 2017 Around one in seven gay and bisexual men cured of hepatitis C at major treatment centres in Germany has become reinfected since 2014, according to findings from the German Hepatitis ... Hepatitis A Warning of hepatitis A outbreak among men who have sex with men in Europe Keith Alcorn / 29 March 2017 An outbreak of hepatitis A in Europe has affected 287 people in at least 13 countries, with large numbers of cases in the United Kingdom, Italy, Spain, Germany and the ... ← First12Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive